On Tuesday, Adma Biologics Inc (NASDAQ: ADMA) opened lower -0.52% from the last session, before settling in for the closing price of $15.52. Price fluctuations for ADMA have ranged from $5.08 to $23.64 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 73.38% over the past five years. Company’s average yearly earnings per share was noted 494.87% at the time writing. With a float of $228.54 million, this company’s outstanding shares have now reached $236.38 million.
Let’s look at the performance matrix of the company that is accounted for 624 employees. In terms of profitability, gross margin is 48.79%, operating margin of 30.01%, and the pretax margin is 19.16%.
Adma Biologics Inc (ADMA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Adma Biologics Inc is 3.32%, while institutional ownership is 86.68%. The most recent insider transaction that took place on Nov 22 ’24, was worth 317,250. In this transaction CFO and Treasurer of this company sold 15,000 shares at a rate of $21.15, taking the stock ownership to the 199,433 shares. Before that another transaction happened on Nov 22 ’24, when Company’s President and CEO sold 48,967 for $21.10, making the entire transaction worth $1,033,204. This insider now owns 1,989,007 shares in total.
Adma Biologics Inc (ADMA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 494.87% per share during the next fiscal year.
Adma Biologics Inc (NASDAQ: ADMA) Trading Performance Indicators
Check out the current performance indicators for Adma Biologics Inc (ADMA). In the past quarter, the stock posted a quick ratio of 3.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.53. Likewise, its price to free cash flow for the trailing twelve months is 45.97.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.28, a number that is poised to hit 0.15 in the next quarter and is forecasted to reach 0.70 in one year’s time.
Technical Analysis of Adma Biologics Inc (ADMA)
Adma Biologics Inc (NASDAQ: ADMA) saw its 5-day average volume 2.19 million, a negative change from its year-to-date volume of 2.29 million. As of the previous 9 days, the stock’s Stochastic %D was 18.73%. Additionally, its Average True Range was 0.66.
During the past 100 days, Adma Biologics Inc’s (ADMA) raw stochastic average was set at 3.19%, which indicates a significant decrease from 13.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 23.81% in the past 14 days, which was lower than the 62.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.03, while its 200-day Moving Average is $15.77. Nevertheless, the first resistance level for the watch stands at $15.75 in the near term. At $16.06, the stock is likely to face the second major resistance level. The third major resistance level sits at $16.35. If the price goes on to break the first support level at $15.15, it is likely to go to the next support level at $14.86. The third support level lies at $14.55 if the price breaches the second support level.
Adma Biologics Inc (NASDAQ: ADMA) Key Stats
There are currently 236,390K shares outstanding in the company with a market cap of 3.65 billion. Presently, the company’s annual sales total 258,220 K according to its annual income of -28,240 K. Last quarter, the company’s sales amounted to 119,840 K and its income totaled 35,910 K.
